JP Morgan Chase
VYNE icon

JP Morgan Chase’s VYNE Therapeutics VYNE Stock Holding History

JP Morgan Chase’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$86 Hold
146
– – ﹤0.01% 7321
2025
Q4 		$85 Hold
146
– – ﹤0.01% 7228
2025
Q3 		$49 Hold
146
– – ﹤0.01% 7226
2025
Q2 		$241 Sell
146
-5,835
-98% -$7.59K ﹤0.01% 6769
2025
Q1 		$9.45K Buy
5,981
+5,667
+1,805% +$13.9K ﹤0.01% 6321
2024
Q4 		$1.05K Buy
314
+137
+77% +$359 ﹤0.01% 6721
2024
Q3 		$332 Buy
177
+1
+0.6% +$2 ﹤0.01% 6844
2024
Q2 		$347 Buy
176
+7
+4% +$17 ﹤0.01% 6724
2024
Q1 		$520 Buy
169
+23
+16% +$50 ﹤0.01% 6712
2023
Q4 		$341 Hold
146
– – ﹤0.01% 6982
2023
Q3 		$584 Buy
146
+138
+1,725% +$602 ﹤0.01% 6703
2023
Q2 		$32 Hold
8
– – ﹤0.01% 6766
2023
Q1 		$0 Sell
8
-2
-20% -$7 ﹤0.01% 7269
2022
Q4 		$0 Hold
10
– – ﹤0.01% 7039
2022
Q3 		$0 Hold
10
– – ﹤0.01% 6893
2022
Q2 		$0 Sell
10
-282
-97% -$2.37K ﹤0.01% 6926
2022
Q1 		$3K Buy
292
+283
+3,144% +$3.36K ﹤0.01% 6389
2021
Q4 		$0 Sell
9
-201
-96% -$4.31K ﹤0.01% 6991
2021
Q3 		$5K Sell
210
-402
-66% -$15.6K ﹤0.01% 6258
2021
Q2 		$38K Sell
612
-3,712
-86% -$294K ﹤0.01% 5809
2021
Q1 		$533K Sell
4,324
-3,894
-47% -$565K ﹤0.01% 4638
2020
Q4 		$935K Buy
8,218
+2,462
+43% +$309K ﹤0.01% 4008
2020
Q3 		$683K Buy
5,756
+403
+8% +$47K ﹤0.01% 3847
2020
Q2 		$667K Sell
5,353
-362
-6% -$49K ﹤0.01% 3727
2020
Q1 		$1.1M Sell
5,715
-1,134
-17% -$356K ﹤0.01% 3335
2019
Q4 		$2.29M Sell
6,849
-572
-8% -$191K ﹤0.01% 3290
2019
Q3 		$2.39M Sell
7,421
-983
-12% -$317K ﹤0.01% 3297
2019
Q2 		$3.36M Sell
8,404
-356
-4% -$176K ﹤0.01% 2968
2019
Q1 		$4.95M Sell
8,760
-1,176
-12% -$564K ﹤0.01% 2591
2018
Q4 		$2.95M Buy
9,936
+1,645
+20% +$736K ﹤0.01% 2986
2018
Q3 		$5.88M Buy
8,291
+6,510
+366% +$4.02M ﹤0.01% 2602
2018
Q2 		$1.04M Buy
1,781
+181
+11% +$141K ﹤0.01% 3814
2018
Q1 		$4.33M Buy
+1,600
New +$3.89M ﹤0.01% 2704

Other funds holding VYNE

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
TC
T3 Companies New York $76.8M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

JP Morgan Chase's VYNE Position: Q1 2026 in Review

JP Morgan Chase held its VYNE Therapeutics (VYNE) position steady in Q1 2026 at 146 shares worth $86. The position accounts for ﹤0.01% of the portfolio, ranked #7321.

JP Morgan Chase first reported a position in VYNE in Q1 2018 and has held it in 33 quarters since. The position peaked at $5.88M in Q3 2018. 45 funds tracked by Wall St. Rank hold VYNE as of Q1 2026.

  • JP Morgan Chase held 146 shares of VYNE Therapeutics worth $86 as of Q1 2026.
  • JP Morgan Chase left its VYNE Therapeutics share count unchanged in Q1 2026.
  • VYNE Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7321 holding.
  • JP Morgan Chase first reported a position in VYNE Therapeutics in Q1 2018 and has held it in 33 quarters since.
  • JP Morgan Chase's VYNE Therapeutics position peaked at $5.88M in Q3 2018.
  • 45 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.